Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
WHO RECOMMENDATION TO TEMPORARILY SUSPEND PROCUREMENT AND USE OF ALL LOTS OF SHAN5 (DTwP-HEPATITIS B-HIB) VACCINE PRODUCED BY SHANTHA BIOTECHNICS, INDIAtriangle.bizjournals.com/triangle/sto... Ben benieuwd wat dat Crucell gaat opleveren....er valt een gat id produktie op te vullen. ivet
invoorentegenspoed schreef:
WHO RECOMMENDATION TO TEMPORARILY SUSPEND PROCUREMENT AND USE
OF ALL LOTS OF SHAN5 (DTwP-HEPATITIS B-HIB) VACCINE PRODUCED BY SHANTHA BIOTECHNICS, INDIA
triangle.bizjournals.com/triangle/sto... Ben benieuwd wat dat Crucell gaat opleveren....er valt een gat id produktie op te vullen.
ivet
Bron? Link slaat op Viehbacher. Dirk
invoorentegenspoed schreef:
WHO RECOMMENDATION TO TEMPORARILY SUSPEND PROCUREMENT AND USE
OF ALL LOTS OF SHAN5 (DTwP-HEPATITIS B-HIB) VACCINE PRODUCED BY SHANTHA BIOTECHNICS, INDIA
triangle.bizjournals.com/triangle/sto... Ben benieuwd wat dat Crucell gaat opleveren....er valt een gat id produktie op te vullen.
ivet
hahahahahhahahhahahhahhhahhahhahahahhhahah!!!!!! yayayayayayayay!!!! ROTFLMAO
Dirk R. Wijnen schreef:
[quote=invoorentegenspoed]
WHO RECOMMENDATION TO TEMPORARILY SUSPEND PROCUREMENT AND USE
OF ALL LOTS OF SHAN5 (DTwP-HEPATITIS B-HIB) VACCINE PRODUCED BY SHANTHA BIOTECHNICS, INDIA
triangle.bizjournals.com/triangle/sto... Ben benieuwd wat dat Crucell gaat opleveren....er valt een gat id produktie op te vullen.
ivet
[/quote]
Sorry, moet zijn:
www.who.int/immunization_standards/va... Bron?
Link slaat op Viehbacher.
Dirk
www.who.int/immunization_standards/va...
Can't find this story on Google or on the link provided. Can anyone confirm...this is big if it is true.
waarschijnlijk verkeerde toets bij copy/paste, waardoor voorlaatste link per abuis werd vermeld, dus nog maar een keertje ter verduidelijking:www.who.int/immunization_standards/va... misschien is er een moderator in de zaal die de link in de eerste posting wil vervangen voor deze hierboven? bvd ivet
Joint WHO-UNICEF Statement 2 12 March 2010 WHO RECOMMENDATION TO TEMPORARILY SUSPEND PROCUREMENT AND USE OF ALL LOTS OF SHAN5 (DTwP-HEPATITIS B-HIB) VACCINE PRODUCED BY SHANTHA BIOTECHNICS, INDIA As of 12 March 2010 the World Health Organization (WHO) recommends to stop procurement and to suspend use of all lots of the Shan5 vaccine supplied to countries pending ongoing investigations. Countries are advised to put any remaining vaccine in quarantine until further notice. If it is confirmed that the country has received shipments of any lot of Shan5 vaccine, the vaccine should not be used, but kept under recommended storage conditions, clearly marked ‘QUARANTINED; NOT TO BE USED OR DISTRIBUTED’ until further direction is provided by WHO. WHO recommends that countries continue vaccination using pentavalent vaccine from an alternative manufacturer or an alternate DTP-containing vaccine until further notice. Countries may contact WHO and UNICEF country offices for assistance to fill shortfalls in vaccine supply as a result of the temporary suspension
Zoals al meermaals in de praktijk bewezen 'haast en spoed zijn zelden goed'...
Juiste keuze mbt positionering van Crucell als betrouwbare leverancier wordt hiermee mooi onderstreept. Ook op lange termijn een gunstige ontwikkeling. Bij Crucell viel al langer een EZDG mbt Shanta en produktlevering te beluisteren..
www.who.int/immunization_standards/va... (vervolg) History of temporary suspension • On 19 February 2010, WHO recommended the temporary suspension of the distribution and use of specific lots of Shan5 vaccine due to the presence of a white sediment which sticks to the glass of the vaccine vial that is difficult or impossible to re-suspend with vigorous shaking (flocculation).This action was taken as a precautionary measure pending investigation of vaccine quality complaints from Colombia, Comoros and Nepal. • Countries where the affected lots were distributed were contacted by WHO and requested to check all the available lots of the Shan5 vaccine. Some countries reported that additional lots that were not included in the temporary suspension also showed a similar problem. • For instance, the Democratic Republic of the Congo reported that 15 out of 24 lots checked showed the presence of the above-mentioned white sediment that could not be re-suspended. In addition, Médecins sans Frontières reported to WHO a similar complaint concerning a lot number that was not included in the lots initially suspended on 19 February; this issue was reported directly to the manufacturer in 2009. • Distribution information indicates that the Shan5 vaccine had been supplied through UN agencies or by direct procurement to Central African Republic, Chad, Colombia, 1 Comoros, Democratic Republic of the Congo, Lao People's Democratic Republic, Mauritania, Mozambique, Nepal, Nicaragua, Pakistan, Republic of Congo and Tanzania. Supply of alternative vaccine • UNICEF Supply Division is working with the country offices to ensure prompt supply of alternative product to enable resumption of vaccination. Countries are encouraged to ensure that UNICEF Country Offices are included on all aspects of dealing with this issue and kept closely informed. UNICEF country offices will provide details of quantities and cold storage requirements of the first possible shipment of new vaccines. Countries need to review and confirm they have sufficient cold storage capacity and to inform whether there are any other impediments in accepting the delivery, such as registration requirements, etc.. • As the suspension is a precautionary measure pending the outcome of an investigation, and as long as the supplier had not recalled the vaccine, any claims processing is pending the outcome and conclusion of the investigation. WHO will keep UNICEF and the countries informed of the timeline for this. • In this initial phase, the focus is on ensuring new vaccine deliveries to countries so vaccination can be resumed. Beyond the immediate supply, UNICEF will work with countries and partners to assess the funding and vaccine requirement for the rest of 2010 with a view to identifying solutions. Shan5 vaccine quality and safety • None of the information available to date suggests a vaccine safety problem with the Shan5 vaccine. • No adverse events following immunization with Shan5 have been reported to WHO. • No other vaccine quality complaints besides the flocculation described above have been reported to WHO. • A vaccine quality investigation by the manufacturer and WHO is ongoing. The available information to date is insufficient to make conclusions about the potential causes of the flocculation as reported. • The manufacturer's Quality Assurance Department has performed investigations that include: review of the batch records for deviations; changes in the manufacturing process including raw materials; review of the cold chain during transportation of the vaccines (temperature monitoring devices); and retesting of the retention samples. Additional Research and Development Department experiments are being performed by the manufacturer. • WHO is conducting a vaccine quality review, including independent testing by WHO- contracted laboratories. This will include scanning electron microscopy (SEM) and X-ray elemental analysis of particles in SEM — procedures that are not routinely used in the quality control of the vaccines. Further advice will be issued by WHO/UNICEF pending the outcome of the investigation performed by the manufacturer and WHO. Shan5 vaccine composition and WHO prequalification: Shan5 is a combined, pentavalent vaccine containing diphtheria, tetanus, whole cell pertussis recombinant DNA, hepatitis B, and Hib components. The vaccine is absorbed onto aluminium salts as an adjuvant and preserved with thiomersal. 2 Shan5 is a WHO prequalified vaccine supplied through UN agencies. Between January 2008 and February 2010 approximately 23 945 082 doses of this vaccine have been supplied through UNICEF and the Revolving Fund of the Pan-American Health Organization. The vaccine is also procured directly for use by public immunization services in a number of countries. Shan5 vaccine currently remains on the WHO list of prequalified vaccines supplied through UN agencies. The WHO web page on prequalification indicates that the vaccine is temporarily suspended pending the outcome of the investigation. __________________ This WHO-UNICEF joint statement supplements a previous communication by WHO to UNICEF, WHO Regional Advisers for Immunization and Vaccine Quality, and the Global Alliance for Vaccines and Immunisation advising of the temporary suspension of specific lots of Shan5 vaccine produced by Shantha Biotechnics India, and actions to be taken. 3
Maw EXTRA druk op Shantha vanuit WHO... (mogelijk omwille van een prul) (Wat zegt de project-controller daarover ? Aja, het gaat ze waarschijnlijk VEEL EXTRA geld kosten)
Merkwaardig dat de koers hier nog pas "matig" op heeft gereageerd. Dit bericht lijkt mij zeer gunstig voor zowel de volumes als de prijzen van de aanstaande QV-contracten. Ik heb mijn handelsvoorraad in ieder geval even stevig aangevuld.
History of temporary suspension • On 19 February 2010, WHO recommended the temporary suspension of the distribution and use of specific lots of Shan5 vaccine due to the presence of a white sediment which sticks to the glass of the vaccine vial that is difficult or impossible to re-suspend with vigorous shaking (flocculation).This action was taken as a precautionary measure pending investigation of vaccine quality complaints from Colombia, Comoros and Nepal. • Countries where the affected lots were distributed were contacted by WHO and requested to check all the available lots of the Shan5 vaccine. Some countries reported that additional lots that were not included in the temporary suspension also showed a similar problem. • For instance, the Democratic Republic of the Congo reported that 15 out of 24 lots checked showed the presence of the above-mentioned white sediment that could not be re-suspended. In addition, Médecins sans Frontières reported to WHO a similar complaint concerning a lot number that was not included in the lots initially suspended on 19 February; this issue was reported directly to the manufacturer in 2009. • Distribution information indicates that the Shan5 vaccine had been supplied through UN agencies or by direct procurement to Central African Republic, Chad, Colombia, Comoros, Democratic Republic of the Congo, Lao People's Democratic Republic, Mauritania, Mozambique, Nepal, Nicaragua, Pakistan, Republic of Congo and Tanzania. Kortom: Er is een wittige neerslag onstaan in de buisjes Shan5, die niet/moeilijk meer op te lossen is door te schudden. Waarschijnlijk is/zijn 1 of meer van de componenten van het vaccin neergeslagen. Uiteraard kan een vaccin met neerslag niet meer worden ingespoten. De know-how die het in Quivaxem voor het eerst mogelijk maakte om de vijf pentavalent componenten allemaal op te lossen en opgelost te HOUDEN, blijkt behoorlijk ingewikkeld. Het gekke is daarbij dat Shanta die know-how van Berna heeft ,wat royalties voor Crucell betekent: zie bv. pagina 30 van:hugin.info/132631/R/1359009/331102.pdf • Tender period 2010-2012: new Indian competition from Shantha (royalties for Crucell), Panacea • Crucell has stake in Shantha/Sanofi Pasteur pentavalent vaccine. Dus het zit hem bij Shanta dan wellicht niet in de know-how, maar in de juiste uitvoering daarvan? In ieder geval hele slechte zaak voor Shanta. Goed voor Crucell als vervangende leverancier, maar slecht voor 't imago voor pentavalent vaccins als geheel, dus ook 'n beetje voor Crucell.
xynix schreef:
Merkwaardig dat de koers hier nog pas "matig" op heeft gereageerd. Dit bericht lijkt mij zeer gunstig voor zowel de volumes als de prijzen van de aanstaande QV-contracten.
Ik heb mijn handelsvoorraad in ieder geval even stevig aangevuld.
hou er rekening mee dat koers en fundamenten niet één op één bewegen... CRXL is m.i. een prima belegging, maar wat het bedrijf presteert en wat de koers 'presteert', loopt nog wel eens uiteen. mvg ivet
Het is in geval van Crucell al 145 miljoen keer goed gegaan. Dus vooral shame on Shanta.
ronbanged2 schreef:
Can anyone confirm...this is big if it is true.
...the stealing of market share outside of India by Panacea and Shantha...
Kom er maar in met de schattingen wat dit voor 't marktaandeel van Crucell betekent.
maxen schreef:
[quote=ronbanged2]
Can anyone confirm...this is big if it is true.
...the stealing of market share outside of India by Panacea and Shantha...
[/quote]
Kom er maar in met de schattingen wat dit voor 't marktaandeel van Crucell betekent.
Nou, geef mij maar liever een PB van Crucell over extra verkopen... Kom op, Oya: doe je best en ga er intern voor!
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
901,68
0,00%
EUR/USD
1,0878
-0,01%
FTSE 100
8.232,04
0,00%
Germany40^
18.516,40
+0,60%
Gold spot
2.337,14
+0,44%
NY-Nasdaq Composite
16.857,05
+0,17%
Stijgers
Dalers